In terms of therapeutic interventions the authors make the following recommendations: Interventions for gastro-oesophageal reflux disease (GORD) • Offer patients who have GORD a full-dose PPI for 1 or 2 months. • If symptoms recur following initial treatment, offer a PPI at the lowest dose possible to control symptoms, with a limited number of repeat prescriptions. Interventions for peptic ulcer disease • Offer H. pylori eradication therapy to H. pylori-positive patients who have peptic ulcer disease. • For patients using NSAIDs with diagnosed peptic ulcer, stop the use of NSAIDs where possible. Offer full-dose PPI or H2 receptor antagonist (H2RA) therapy for 2 months to these patients and, if H. pylori is present, subsequently offer eradication therapy. Interventions for non-ulcer dyspepsia • Management of endoscopically determined non-ulcer dyspepsia involves initial treatment for H. pylori if present, followed by symptomatic management and periodic monitoring. • Re-testing after eradication should not be offered routinely, although the information it provides may be valued by individual patients. Reviewing patient care • Offer patients requiring long-term management of dyspepsia symptoms an annual review of their condition, encouraging them to try stepping down or stopping treatment. • A return to self-treatment with antacid and/or alginate therapy (either prescribed or purchased over-the-counter and taken as required) may be appropriate. H. pylori testing and eradication • H. pylori can be initially detected using either a carbon-13 urea breath test or a stool antigen test, or laboratory-based serology where its performance has been locally validated. • Office-based serological tests for H. pylori cannot be recommended because of their inadequate performance. • For patients who test positive, provide a 7-day, twice-daily course of treatment consisting of a full-dose PPI with either metronidazole 400 mg and clarithromycin 250 mg or amoxicillin 1 g and clarithromycin 500 mg.